Press Release

Seraxis Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy.

admin

November 12, 2018

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.

Seraxis Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy.

About Seraxis, Inc.

Generation and selection of pluripotent stem cells for robust differentiation to insulin-secreting cells capable of reversing diabetes in rodents.

Concise Review: Lessons Learned from Islet Transplant Clinical Trials in Developing Stem Cell Therapies for Type 1 Diabetes.

Related articles

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated T1D Biotech Company

Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes.

Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D.